State-of-the-Art
Flashlight
new issue
A State-of-the-Art on TAVI and coronary interventions; early haemodynamic valve deterioration after TAVI; 30-day outcomes of redo-TAVI with SAPIEN 3; Unica device for tricuspid regurgitation; the UNICORN technique in native valves; and more
Debate
There is an ongoing debate over whether prasugrel or ticagrelor should be the preferred P2Y12 inhibitor for patients with acute coronary syndromes, as the available evidence comparing the two remains inconclusive.
Viewpoint
Original Research
Original Research
Editorial
EuroPCR2026
The EuroIntervention Awards 2026 recognise the authors, reviewers, editors and contributors whose work has had an outstanding impact on the interventional cardiovascular community over the past year. Discover the full list of winners, finalists and special mentions across all categories, highlighting excellence in scientific research, innovation, education and digital engagement.
Original Research
Original Research
Editorial
Original Research
This pilot randomized study explored whether short-term glucocorticoid therapy could reduce the need for permanent pacemaker implantation (PPI) after TAVI, while assessing feasibility, safety, and early efficacy signals. Patients received either standard care or a steroid regimen with methylprednisolone before TAVI and prednisone for 5 days after, with outcomes including PPI rates, new left bundle branch block, mortality, and procedural complications
Editorial
State-of-the-Art
